X

Vous n'êtes pas connecté

Maroc Maroc - ONCOLOGYNEWS.COM.AU - A La Une - 17/08/2024 14:16

Improved chemokine homing enhances CAR T–cell therapy for osteosarcoma

Chimeric antigen receptor (CAR) T–cell immunotherapy re-engineers a patient’s immune cells to target cancer cells. While successful in some types of leukaemia, the approach has yet to realise its potential against paediatric solid tumours. Scientists at St. Jude Children’s Research Hospital have identified a way to improve CAR T–cell homing – a T cell’s ability [...]

Articles similaires

Novel material to enhance cancer immunotherapy

oncologynews.com.au - 23/Jan 05:22

Cancer has long remained a leading cause of death worldwide and in Hong Kong, accounting for 30% of all disease-related deaths in the city in 2025....

Novel material to enhance cancer immunotherapy

oncologynews.com.au - 23/Jan 05:22

Cancer has long remained a leading cause of death worldwide and in Hong Kong, accounting for 30% of all disease-related deaths in the city in 2025....

New research uncovers molecular ‘safety switch’ shielding cancers from immune attack

oncologynews.com.au - 23/Jan 16:31

Australian researchers have discovered that the TAK1 gene helps cancer cells survive immune system attacks, revealing a mechanism that may limit the...

New research uncovers molecular ‘safety switch’ shielding cancers from immune attack

oncologynews.com.au - 23/Jan 16:31

Australian researchers have discovered that the TAK1 gene helps cancer cells survive immune system attacks, revealing a mechanism that may limit the...

Sorry! Image not available at this time

CAR-T Clinical Trial Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry ...

wn.com - 00:13

DelveInsight’s “CAR T-Cell Therapy Pipeline Insight 2025” report provides comprehensive insights about 180+ companies and 200+...

Sorry! Image not available at this time

CAR-T Clinical Trial Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry ...

wn.com - 00:13

DelveInsight’s “CAR T-Cell Therapy Pipeline Insight 2025” report provides comprehensive insights about 180+ companies and 200+...

Sorry! Image not available at this time

Creative Biolabs Unveils CAR-T Cell Therapy Solutions to Accelerate Immuno-Oncology Development

wn.com - 30/Jan 23:52

With over two decades of experience in cellular engineering, Creative Biolabs remains a trusted partner for scientists navigating the complexities of...

Sorry! Image not available at this time

Creative Biolabs Unveils CAR-T Cell Therapy Solutions to Accelerate Immuno-Oncology Development

wn.com - 30/Jan 23:52

With over two decades of experience in cellular engineering, Creative Biolabs remains a trusted partner for scientists navigating the complexities of...

Sorry! Image not available at this time

Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis

africanewswire.za.com - 30/Jan 13:11

Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s...

Sorry! Image not available at this time

Car T Cell Therapy For Multiple Myeloma Pipeline 2025: FDA Approvals and Clinical Trials Landscape ...

wn.com - 26/Jan 15:20

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Car T Cell Therapy For Multiple Myeloma pipeline constitutes 5+ key...